Every 424B that Redhill Biopharma Ltd. (RDHL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RDHL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RDHL filings page.
RedHill Biopharma Ltd. is registering up to 26,228,573 American Depositary Shares (ADSs) for resale by existing holders. These ADSs are issuable upon exercise of pre-funded, Series A-1, Series A-2 and placement agent warrants from a June 2026 private placement, with each ADS representing 10,000 ordinary shares.
The company will not receive proceeds from resale of the ADSs. It would receive up to approximately $13.8 million in gross proceeds only if all warrants are exercised for cash, which it currently plans to use for working capital, research and development and general corporate purposes. ADSs outstanding were 6,080,920 at the time of the offering summary.
RedHill describes significant potential dilution from options, RSUs and warrants and details past and current challenges meeting Nasdaq listing standards, including the $1.00 minimum bid price, stockholders’ equity requirements and a proposed $5 million market value threshold. Its independent auditors have previously highlighted substantial doubt about the company’s ability to continue as a going concern.
RedHill Biopharma Ltd. amends its Form F-3 prospectus supplement to increase the amount of American Depositary Shares available under its At The Market sales agreement by up to $2,128,000. The supplement states this amount is in addition to $49,690 of ADSs previously sold under the same agreement.
The supplement cites General Instruction I.B.5 of Form F-3 and reports the aggregate market value of Ordinary Shares held by non-affiliates as $6,534,464 based on 59,949,221,000 Ordinary Shares held by non-affiliates (represented by 5,994,922 ADSs and a per-ADS price of $1.09 as of April 30, 2026. The ADSs trade on Nasdaq under the symbol RDHL; the last reported sale price on June 26, 2026 was $0.8786 per ADS.
RedHill Biopharma Ltd. supplements its Form F-3 prospectus to increase the maximum aggregate offering price available under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC by $1,587,708. This addition is subject to the $1,854,911 limit imposed by General Instruction I.B.5 of Form F-3 and follows prior sales of 92,458 ADSs for aggregate gross proceeds of $267,204. The company reports a public float market value of $5,564,735.58 based on 51,052,621,000 ordinary shares held by non-affiliates (equivalent to 5,105,262 ADSs at $1.09 per ADS as of April 30, 2026). The ADSs trade on Nasdaq under the symbol RDHL.
RedHill Biopharma is registering up to 6,465,559 ADSs for resale by YA II PN, LTD. under a standby equity purchase arrangement. The ADSs cover up to 5,000,000 Advance Shares, 386,593 Initial Equity Shares, 590,446 ADSs from pre-funded warrants and 488,520 Commitment Shares.
Under the Purchase Agreement, YA has committed, subject to conditions and ownership caps, to buy up to $25.0 million of ADSs over 36 months, plus $1.0 million already raised via Initial Equity Shares and pre-funded warrants. As of January 21, 2026, 5,112,885 ADSs were outstanding; if all 6,465,559 registered ADSs were issued, they would represent about 55.84% of outstanding ADSs.
RedHill Biopharma Ltd. is increasing the maximum aggregate amount of American Depositary Shares it may sell under its at-the-market offering agreement with H.C. Wainwright & Co. to $352,267. Each ADS represents ten thousand Ordinary Shares, and this new limit applies only to future sales under the existing Sales Agreement.
As of this supplement, the company’s public float under Form F-3 was valued at $11,448,803.52, based on 45,431,765,990 Ordinary Shares held by non-affiliates, which would be represented by 4,543,176 ADSs at a price of $2.52 per ADS as of October 1, 2025. Over the prior 12 months, RedHill sold 890,001 ADSs via the program for approximately $3.4 million in gross proceeds, and any further increases in sale capacity will require an additional prospectus supplement.
RedHill Biopharma Ltd. filed a prospectus supplement for the resale, from time to time, of up to 4,582,582 American Depositary Shares (ADSs), each representing 10,000 ordinary shares. The registration covers ADSs that may be issued to Alumni Capital LP under an Any Market Purchase Agreement establishing a committed equity line, including up to 333,333 ADSs issuable upon exercise of an unregistered commitment warrant.
The supplement also discloses a Letter Agreement dated October 20, 2025, which increases the beneficial ownership limitation for purchases made via Forward Purchase Notices from 4.99% to 9.99%. Purchases via Regular Purchase Notices remain capped at 4.99%. These limits prevent directing purchases that would result in Alumni and its affiliates exceeding the specified ownership thresholds at any single point in time.